Fairmount Funds Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Fairmount Funds Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-469,264	Closed	-$24.3M	–	21
2022 Q3	$24.3M	Hold	469,264	–	–	4.28%	12
2022 Q2	$22.2M	Hold	469,264	–	–	5.08%	10
2022 Q1	$33.4M	Buy	469,264 +81,864	+21%	+$5.33M	7.9%	5
2021 Q4	$29M	Buy	387,400 +70,448	+22%	+$5.53M	9.55%	3
2021 Q3	$18M	Buy	316,952 +138,894	+78%	+$6.87M	6.55%	5
2021 Q2	$7.84M	Buy	178,058 +6,911	+4%	+$338K	3.22%	15
2021 Q1	$8.44M	Buy	171,147 +20,714	+14%	+$1.03M	3.56%	13
2020 Q4	$6.33M	Sell	150,433 -11,803	-7%	-$519K	2.27%	15
2020 Q3	$7.43M	Sell	162,236 -7,713	-5%	-$374K	3.15%	12
2020 Q2	$8.53M	Hold	169,949	–	–	3.81%	13
2020 Q1	$8.74M	Buy	169,949 +8,000	+5%	+$426K	5.3%	10
2019 Q4	$10M	Buy	+161,949	New	+$10M	6.06%	8

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Fairmount Funds Management's ENTA Position: Q4 2022 in Review

Fairmount Funds Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2022, closing a stake of 469,264 shares — an estimated $24.3M sold.

Fairmount Funds Management first reported a position in ENTA in Q4 2019 and held it in 12 quarters. The position peaked at $33.4M in Q1 2022. 146 funds tracked by Wall St. Rank hold ENTA as of Q4 2022.

Fairmount Funds Management reported no remaining Enanta Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Fairmount Funds Management sold 469,264 Enanta Pharmaceuticals shares in Q4 2022, an estimated $24.3M.
Fairmount Funds Management first reported a position in Enanta Pharmaceuticals in Q4 2019 and held it in 12 quarters.
Fairmount Funds Management's Enanta Pharmaceuticals position peaked at $33.4M in Q1 2022.
146 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2022.

Based on Fairmount Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.